Clinical Case Analysis: 17-Year-Old Female with VKH Disease and New-Onset Psychosis

Overview and Clinical Framing

Question 1: Differential Diagnosis (Ranked by Probability)

Question 2: Steroid-Induced Psychosis - Timeline Analysis

Typical Steroid Psychosis Profile

• Onset: Median 11.5-12.5 days after initiation (Lewis and Smith); most cases occur within the first few weeks of high-dose therapy.
• Dose relationship: Incidence rises sharply above 40 mg prednisone/day equivalent. Studies show 1.3% incidence at ≤40 mg/day, 4.6% at 41-79 mg/day, and 18.4% at ≥80 mg/day.
• Symptoms: Delusions, auditory/visual hallucinations, euphoria, mania, depression, anxiety, insomnia. Depression and insomnia are the most frequent early symptoms; auditory hallucinations with impaired insight can occur (Adams and Victor's Principles of Neurology, 12th Ed., p. 1192).
• Risk factors: Female sex (higher risk), high cumulative dose, rapid administration. History of prior psychiatric illness is not reliably predictive (Adams and Victor's, 12th Ed.; Husain & Ahmad, Psychopharmacology 2026 [PMID: 42132956]).

Analysis of This Case's Timeline

1. Irregular adherence creates a pattern of repeated re-exposure rather than a single sustained course. Each time the patient restarts prednisolone after a gap, the HPA axis is subject to a new surge in exogenous glucocorticoid. This "start-stop" pattern can produce cumulative HPA dysregulation.
2. Recent worsening occurring 2 days after restarting prednisolone at 10 mg/day is notable. While 10 mg/day is a low dose for classical steroid psychosis, case reports of acute psychosis at low doses exist (Lesko et al., Cureus 2021 - cited in Nasereddin et al., Diseases 2024 [PMID: 39727630]).
3. Mechanistically, corticosteroids dysregulate the HPA axis, increase dopaminergic activity through induction of tyrosine hydroxylase, alter glutamate/serotonin neurotransmission, and cause structural changes in the hippocampus and amygdala (Nasereddin et al. 2024 [PMID: 39727630]; Husain & Ahmad 2026 [PMID: 42132956]).
4. Steroid psychosis is a diagnosis of exclusion and cannot be confirmed until other causes are ruled out, especially in a patient with ongoing autoimmune disease.

Question 3: VKH CNS Involvement

"Prodromal phase lasting a few days: neurological (meningitis and rarely encephalopathy with cranial nerve paresis and other focal lesions) and auditory manifestations (tinnitus, vertigo and deafness)."

• Kanski's Clinical Ophthalmology, 10th Ed.

"Prodromal: loss of high-frequency hearing, tinnitus, meningismus, encephalopathy, and hypersensitivity of the skin to touch."

• Wills Eye Manual

"Neurologic: meningeal irritation/aseptic meningitis: headache, neck stiffness and photophobia; cranial nerve palsies; encephalopathy: altered mental status, seizures or focal neurological deficits."

• Review of Ophthalmology (Shah & Fell, 2025)

Key Points Regarding VKH Neuropsychiatric Involvement in This Patient

1. Typically occurs in the prodromal phase, before or at the time of ocular disease onset. In this patient, ocular symptoms began November 2025. CNS symptoms emerging in April 2026 (~5-6 months later) would be atypical for classic VKH prodromal CNS disease.
2. Chronic/recurrent VKH can have flares, particularly when corticosteroids are inadequately tapered or adherence is poor. A VKH flare with CNS involvement months into the disease course is possible but less well-described.
3. Psychosis is not a classic VKH neurological symptom. Encephalopathy, meningeal signs, seizures, and cranial nerve palsies are described. However, a published case report (Kheradmand & Safarzadeh, IJ Psychiatry and Behavioral Sciences) documents VKH presenting with a schizophrenia-spectrum disorder for the first time - demonstrating that the overlap can occur.
4. CSF would be informative: VKH classically shows transient lymphocytic pleocytosis and melanin-containing macrophages on lumbar puncture (Kanski's, p. 5042). A normal CSF would argue against active VKH meningeal inflammation.

Question 4: Primary Psychiatric Disorders in a 17-Year-Old Female

Question 5: Neurological and Autoimmune Causes to Exclude

Must Exclude:

1. Anti-NMDA receptor encephalitis - The single most important mimicker. Characterized by auditory hallucinations, behavioral disturbance, psychosis, and autonomic instability in young females. In the largest systematic review (Warren et al., Acta Psychiatrica Scandinavica 2018 [PMID: 29992532], n=706): mean age 22.6 years, F:M ratio 3.5:1; psychosis in 45.8%; EEG abnormal in 83%; MRI abnormal in 35.6%. This patient fits the demographic perfectly. Diagnosis requires CSF anti-NMDAR antibodies. Features atypical for pure schizophrenia include severe agitation, catatonia, and abnormal EEG (Warren et al. 2018). Anti-NMDA encephalitis may also be triggered or worsened in the context of existing autoimmune disease.
2. Other autoimmune encephalitides - LGI1 antibody (faciobrachial dystonic seizures, hyponatremia), CASPR2, AMPA-R, GABA-B receptor antibodies. Serum and CSF antibody panel needed.
3. CNS tuberculosis - India has a high TB burden. This immunosuppressed patient (steroids + azathioprine) is at elevated risk. TB meningitis can present atypically with psychiatric symptoms. Evaluate with CSF, chest X-ray, IGRA, ADA.
4. Other CNS infections - Cryptococcal meningitis, CMV, HSV encephalitis (less likely without fever/acuity), EBV, toxoplasma in immunosuppressed host.
5. Systemic Lupus Erythematosus (SLE) with CNS involvement - Overlaps with VKH in demographics. NPSLE is characterized by psychosis, seizures, cognitive changes. ANA, anti-dsDNA, complement levels needed.
6. Neurosarcoidosis - ACE level, chest imaging, granulomatous changes on MRI.
7. Azathioprine toxicity/CNS effects - Rare but documented; check FBC for myelotoxicity.
8. Thyroid dysfunction - Hyperthyroidism and hypothyroidism both produce neuropsychiatric symptoms. TSH/FT4 needed.
9. Electrolyte disturbances - Hyponatremia (SIADH, Addisonian crisis during steroid tapering), hypo/hyperglycemia, hypercalcemia.
10. Adrenal insufficiency - Abrupt/irregular steroid use can precipitate relative adrenal insufficiency with cognitive/psychiatric manifestations.

Question 6: Recommended Investigations

Urgent (Within 24-48 Hours)

• Serum electrolytes (Na, K, Ca, Mg, phosphate)
• Random blood glucose and HbA1c
• Complete blood count and differential (azathioprine-related cytopenias)
• Renal function tests, liver function tests
• Serum cortisol (morning) - to assess adrenal axis
• Thyroid function tests (TSH, free T4)
• C-reactive protein, ESR (inflammatory markers)

• MRI brain with gadolinium (contrast-enhanced, including FLAIR, DWI, T2 sequences)
  • To exclude CNS inflammation, encephalitis, demyelination, mass lesion
  • VKH with CNS involvement may show leptomeningeal enhancement
  • Anti-NMDA encephalitis: MRI may be normal (35% abnormal) or show FLAIR changes in temporal/frontal regions
  • Note: CT brain is NOT sufficient to exclude these diagnoses

• Urgent EEG - anti-NMDA receptor encephalitis shows EEG abnormality in ~83% of cases (Warren et al. 2018 [PMID: 29992532])
• Look for non-convulsive status epilepticus, slow background, extreme delta brush pattern

Intermediate Priority (48-72 Hours)

• Opening pressure
• CSF cell count, protein, glucose
• CSF culture and sensitivity, India ink, cryptococcal antigen
• CSF for AFB smear, TB PCR (given Indian origin, immunosuppression)
• CSF anti-NMDAR antibodies (most sensitive test)
• CSF viral PCR (HSV, EBV, CMV, enterovirus)
• CSF oligoclonal bands
• CSF melanin-laden macrophages (VKH-specific finding)

• Anti-NMDAR antibodies (serum - less sensitive than CSF but useful)
• ANA, anti-dsDNA, complement C3/C4, anti-phospholipid antibodies (SLE screen)
• ANCA, anti-CCP (vasculitis screen)
• Serum ACE (sarcoidosis)
• Anti-MOG, anti-AQP4 (demyelinating disease)

• HIV serology
• Hepatitis B and C (prior to any escalation of immunosuppression)
• VDRL/RPR (syphilis), FTA-ABS
• T-spot/IGRA for TB
• Blood cultures if febrile

• Slit-lamp examination for signs of VKH flare (anterior chamber cells, KPs)
• OCT macula for subretinal fluid/choroidal thickening
• Fundus fluorescein angiography if recurrence suspected

• Formal psychiatric evaluation using standardized tools (BPRS, PANSS, MADRS)
• Full cognitive assessment
• Family history of psychiatric and autoimmune illness
• Substance use history (cannabis is a key precipitant of psychosis in adolescents)

• Urine pregnancy test
• Urine toxicology screen (cannabis, amphetamines, others)
• HLA typing (HLA-DR1, HLA-DR4 associated with VKH - confirms diagnosis retroactively)

Question 7: Urgent Red Flags Requiring Emergency Evaluation

Question 8: Steroid and Azathioprine Management - Balancing Psychiatric Risk and VKH Control

Prednisolone Management

• The re-exposure phenomenon (restarting after irregularity) is mechanistically significant
• At this dose, VKH relapse risk from cessation is HIGH - Medscape notes therapy should not be discontinued during the first 3 months, and inflammation may recur up to 9 months after stopping (Wills Eye Manual, p. 4740)
• Steroid taper of 5 mg/month is appropriate but must be done with strict adherence rather than irregular use

• Do not abruptly stop prednisolone without first establishing azathioprine is at therapeutic levels and ophthalmic disease is quiescent
• Continue current dose (10 mg/day) with strict supervised dosing
• Ensure adherence monitoring is implemented
• Reassess dose reduction only after psychiatric and ophthalmic status stabilized

Azathioprine

• Azathioprine 75 mg/day serves as the steroid-sparing agent, reducing cumulative steroid burden over time
• Check thiopurine methyltransferase (TPMT) enzyme activity and FBC to ensure no toxicity
• If VKH is stable on azathioprine + low-dose prednisolone, this is the preferred long-term strategy per current guidelines (Medscape VKH treatment guidelines)
• Do not discontinue azathioprine without specialist review

Psychiatric Medication

• Low-dose atypical antipsychotic is appropriate: risperidone (0.5-2 mg/day), quetiapine, or olanzapine in low doses
• Lithium may be used for manic features when continued steroids are necessary (Adams and Victor's Neurology, 12th Ed.)
• Avoid tricyclic antidepressants (evidence of exacerbation of steroid-induced mood symptoms)

Question 9: Literature on Delayed-Onset and Tapering-Phase Steroid Psychosis

Typical Onset Pattern

"The psychosis usually develops over a period of a few days after the patient has received the medication for a week or more."

• Adams and Victor's Principles of Neurology, 12th Ed.

Delayed and Low-Dose Psychosis

Psychosis During Tapering / Re-exposure

• Irregular steroid use creates HPA axis instability - periods of HPA suppression followed by stimulation from re-dosing
• The corticosteroid-to-endogenous-cortisol ratio changes dramatically with each irregular dose
• Dopaminergic dysregulation may persist beyond individual doses
• There are case reports of psychiatric symptoms worsening during taper (though mania is more commonly described at initiation; depression more commonly at tapering)
• The adrenal insufficiency state during taper can itself produce confusion, psychomotor changes, and depression that mimics or compounds psychosis

Question 10: Most Likely Explanation and Immediate Next Steps

Most Likely Explanation (Integrated Assessment)

• Age 17, female, auditory hallucinations with derogatory content, impaired insight, insomnia persisting for "several months" without full remission
• Steroid use may have lowered the threshold for psychosis expression in a genetically/constitutionally vulnerable individual
• The worsening with re-exposure could represent an additive pharmacological trigger in someone already developing schizophrenia or a related disorder
• Duration of symptoms (several months) is more consistent with schizophrenia spectrum than typical steroid psychosis, which usually remits within weeks of dose reduction

• Temporal relationship exists (even if delayed)
• Female sex, irregular adherence with re-exposure, HPA dysregulation
• Less likely to be sole explanation given the prolonged duration and low current dose

• Young female with underlying autoimmune condition is classic demographic
• Must be actively excluded with CSF antibodies and EEG before attributing to steroids or primary psychiatric disease

Immediate Next Steps (Priority Order)

• Assess for suicidal ideation, self-harm risk, risk to others
• Assess level of consciousness and orientation
• Check vitals (BP, temperature, HR) - screen for adrenal crisis, infection
• Decision on inpatient vs. outpatient management

• Ensure she takes her prednisolone consistently with supervision to avoid HPA instability
• Do not abruptly stop

• MRI brain with gadolinium to exclude structural/inflammatory CNS cause
• EEG to exclude non-convulsive status epilepticus and look for encephalitis pattern

• Electrolytes, renal/liver function, glucose, cortisol, TFTs, FBC, CRP/ESR
• Anti-NMDAR antibodies (serum), ANA panel

• CSF for anti-NMDAR antibodies, TB PCR, cell count, culture, melanin macrophages

• Formal psychiatric assessment
• Initiation of low-dose atypical antipsychotic (risperidone 0.5-1 mg at night) to target hallucinations while investigations are underway
• This does NOT worsen the autoimmune workup and provides immediate symptom relief

• Ophthalmology (assess for VKH flare - anterior segment, OCT)
• Neurology (encephalitis workup, EEG interpretation)
• Psychiatry (diagnostic evaluation and psychopharmacology)
• Paediatric Rheumatology/Immunology (overall autoimmune management)
• Infectious Disease (if TB or OI suspected given immunosuppression)

• Explain that the cause is being investigated
• Strict medication adherence is essential
• Avoid sudden steroid changes at home

Summary Table

References

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th Ed. - VKH: classification, CNS features, investigations (p. 5010-5042)
• Wills Eye Manual, 7th Ed. - VKH diagnostic criteria, phases, treatment (p. 4596-4741)
• Adams and Victor's Principles of Neurology, 12th Ed. - Corticosteroid/glucocorticoid psychosis (p. 1192-1197)
• Kaplan and Sadock's Synopsis of Psychiatry - Autoimmune encephalitis mimicking schizophrenia, anti-NMDA encephalitis (p. 2111)
• Neuroscience: Exploring the Brain, 5th Ed. - NMDA receptor autoimmune encephalitis mechanism (p. 4414-4418)

• Nasereddin L et al. "Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications." Diseases 2024 [PMID: 39727630] - HPA axis disruption, dopaminergic/glutamatergic mechanisms, management strategies
• Husain A, Ahmad F. "Corticosteroid-Induced neuropsychiatric manifestations: From pathophysiology to management." Psychopharmacology 2026 [PMID: 42132956] - Most current comprehensive review; incidence 5-20%; female sex as risk factor
• Warren N et al. "Refining the psychiatric syndrome of anti-N-methyl-d-aspartate receptor encephalitis." Acta Psychiatr Scand 2018 [PMID: 29992532] - Systematic review of 706 cases; mean age 22.6 years; F:M 3.5:1; EEG abnormal in 83%
• Kheradmand A, Safarzadeh H. "Vogt-Koyanagi-Harada Disease Presenting as a Schizophrenia Spectrum Disorder." IJ Psychiatry and Behavioral Sciences - First reported case of VKH co-occurring with schizophrenia-spectrum disorder

• Shah V, Fell D. "Vogt-Koyanagi-Harada Syndrome: An Update." Review of Ophthalmology, March 2025 - CNS features including encephalopathy, altered mental status, seizures
• Medscape eMedicine - VKH Treatment: immunomodulatory therapy, taper duration guidance
• PMC7953074 - Pharmacological Management of Steroid-Induced Psychosis: case review supporting atypical antipsychotics (risperidone, haloperidol)

Important Clinical Disclaimer: This analysis is for educational and clinical decision-support purposes. All management decisions, especially medication initiation or changes in a minor with an active autoimmune condition, must be made by qualified treating clinicians following direct patient assessment, institutional protocols, and applicable ethical and regulatory frameworks.The analysis above is drawn from multiple authoritative sources consulted in parallel. Here is a brief orientation to help navigate the report:

1. Anti-NMDA receptor encephalitis - must be excluded first because it is treatable with immunotherapy, presents identically to this case in young women, and has high stakes if missed. CSF antibodies + EEG are the critical tests.
2. First-episode schizophrenia or schizophreniform disorder - the duration ("several months") and clinical profile (derogatory auditory hallucinations, impaired insight) is highly consistent. Steroid use may be coincidental or a threshold-lowering trigger.
3. Steroid-induced psychosis - plausible but the timing (delayed onset at 4-5 months, currently on only 10 mg/day) is atypical. The worsening with re-exposure is the strongest supporting feature. This remains a diagnosis of exclusion.

Addendum: Impact of the 2022 Prior Episode on Clinical Reasoning

What the 2022 Episode Tells Us

• Acute psychosis
• Depressive features
• Possible catatonia
• An identified precipitant: burnout/severe stress reaction
• Resolution (implied, since she had no known ongoing psychiatric history before the current episode)

1. The Revised Diagnostic Hierarchy

2. Bipolar Disorder - Why It Must Be Front and Centre

• Psychosis + depression + possible catatonia at age 13-14
• Triggered by severe stress (burnout reaction - consistent with a hypersensitive affective nervous system)
• Apparent full resolution (which is characteristic of bipolar, not schizophrenia)

• Auditory hallucinations with negative derogatory content (consistent with psychotic depression or mixed state)
• Insomnia (cardinal early symptom of mania/mixed state)
• Worsening with re-exposure to steroids (steroids are a well-established trigger of mania and mixed states)
• Impaired insight

"Treatment with steroids commonly induces further psychiatric complications, including mania and psychosis."

• Kaplan and Sadock's Synopsis of Psychiatry (discussing SLE, but generalizable)

3. Schizophrenia - Why It Remains on the Differential

• Early-onset schizophrenia (EOS, onset before age 18) accounts for approximately 12% of all schizophrenia cases and ~8% are onset before 18 years (Annual Research Review, PMC11920611, 2025)
• The prior 2022 episode may represent the first psychotic episode of schizophrenia, with the current episode being the second episode with incomplete inter-episode recovery
• Diagnostic stability data from Kaplan & Sadock's Comprehensive Textbook: in the Suffolk County prospective cohort, only 27% of initial brief psychotic disorder diagnoses were maintained at 24-month follow-up; 9% were rediagnosed with schizophrenia, 27% with mood disorders - the diagnosis evolves
• The key distinguishing feature between schizophrenia and bipolar with psychosis in this case will be: what was the inter-episode functioning? Full return to premorbid functioning favors bipolar; residual deficit symptoms (flat affect, negative symptoms, social withdrawal, academic decline) favor schizophrenia

4. Impact on Steroid Psychosis Probability

• The 2022 episode occurred without any steroid exposure - proves there is a pre-existing psychotic vulnerability independent of steroids
• The current episode's duration ("several months") far exceeds typical steroid psychosis, which resolves within weeks of dose reduction
• She is currently at a low dose (10 mg/day) - an unlikely driver of sustained new psychosis

• Published guidelines note: "previous diagnosis of mental illness and prior incidence of corticosteroid-induced psychiatric effects are also risk factors" (mypcnow.org, citing multiple clinical series)
• Steroids may have acted as a biological precipitant that unlocked a pre-existing vulnerability
• Irregular adherence (stop-start pattern) creates HPA instability that may trigger mood episodes in someone with affective dysregulation

5. Revised Investigation Priorities

Mandatory New History-Taking

• What was the 2022 episode's exact presentation? Duration? Full catatonia or partial? What treatment was given? How rapidly did it resolve? Was any psychiatric medication given?
• Was a diagnosis made in 2022? Was it labeled reactive psychosis, adjustment disorder, depression with psychotic features?
• Family psychiatric history - bipolar disorder, schizophrenia, psychosis in first/second-degree relatives? (Indian families may have undisclosed or under-diagnosed relatives)
• Developmental and academic history - any prodromal signs of schizophrenia (social withdrawal, decline in functioning, odd beliefs before 2022)?
• Substance use - cannabis use is highly relevant; onset often in early teens in urban Indian adolescents and is a major trigger and perpetuator of psychosis
• Between episodes: did she return fully to baseline social, academic, interpersonal functioning between 2022 and 2025?

Revised Diagnostic Tools

• Formal psychiatric rating scales: PANSS (Positive and Negative Syndrome Scale) to quantify positive, negative, and general psychopathology
• YMRS (Young Mania Rating Scale) - given bipolar possibility and insomnia
• CDSS (Calgary Depression Scale for Schizophrenia) - to separate depressive from negative symptoms
• Structured clinical interview (SCID-5 or Mini-PLUS) to systematically evaluate the full DSM-5 differential
• Catatonia assessment - Bush-Francis Catatonia Rating Scale (if any catatonic features present in 2026 episode)

Neuroimaging in New Context

• MRI brain remains important, but now also to assess for any structural changes suggesting early schizophrenia (subtle hippocampal volume reduction) or mood disorder
• Baseline MRI is useful for future comparison

6. Treatment Implications of the Revised Diagnosis

If Bipolar I with Psychotic Features (Likely)

If Schizophrenia Spectrum (Possible)

The 2026 Catatonia Question

Steroid Management (Unchanged from Prior Analysis)

• Do NOT abruptly stop prednisolone at 10 mg/day - risk of VKH flare and adrenal insufficiency
• Supervised adherence to prevent further HPA disruption
• Coordinate any dose changes with psychiatry to anticipate mood/psychosis fluctuation

7. The Autoimmune-Psychiatric Interface

• VKH is HLA-DR1/HLA-DR4 associated - these HLA alleles have been studied in the context of autoimmune contributions to psychiatric disorders
• Emerging evidence suggests that a subset of schizophrenia cases have autoimmune underpinnings (anti-NMDA, anti-CASPR2, anti-LGI1 antibodies found in psychosis cohorts)
• It is biologically plausible that the same immune dysregulation driving VKH could lower the threshold for neuroinflammatory psychosis
• This does not make it anti-NMDA encephalitis - but it suggests the autoimmune and psychiatric conditions may be mechanistically linked rather than coincidental

Revised Summary: Most Likely Explanation

The most parsimonious and evidence-supported diagnosis is now: a recurrent primary psychiatric disorder (most likely early-onset bipolar I disorder with psychotic features, or schizophrenia spectrum), which has relapsed in the context of multiple biological stressors - active autoimmune disease, irregular corticosteroid exposure, HPA axis dysregulation, and possible ongoing neuroinflammation from VKH.

Immediate Clinical Priority: Clarify the 2022 Episode

"The most critical differential diagnostic issue for both acute and transient psychotic disorder and brief psychotic disorder is to rule out delirium, psychotic disorder due to another medical condition, substance/medication-induced psychotic disorder, and drug or alcohol intoxication."

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry

• Stressor: Bereavement (grandmother's death) → 9th grade
• Withdrawn, anxious, agitated
• ↓ Communication, ↓ self care, ↓ appetite, sleep disturbances
• Acute Psychosis / Depression
• ? Catatonia
• CT/MRI: Normal (ticked ✓)
• Medications prescribed:
  1. Aripiprazole 5mg OD
  2. Risperidone 1mg OD
  3. Lorazepam 1mg - 1-0-1 × 10 days

Updated Analysis: The Case Now Has a Clear Diagnostic Shape

Reading the 2022 Prescription

Stressor: Bereavement (grandmother's death) - 9th Grade (age ~13-14) Symptoms: Withdrawn, anxious, agitated | ↓ Communication | ↓ Self-care | ↓ Appetite | Sleep disturbances Diagnosis written: Acute Psychosis / Depression | ? Catatonia Investigations: CT/MRI Brain - Normal ✓ Treatment prescribed:

• Aripiprazole 5mg once daily
• Risperidone 1mg once daily
• Lorazepam 1mg: 1-0-1 × 10 days

1. Diagnostic Conclusion: This Is Recurrent Psychotic Depression (Most Likely)

Major Depressive Disorder with Psychotic Features - Recurrent

2. The Steroid Question - Now Reframed Definitively

• De novo steroid psychosis: occurs in people with no prior psychiatric history, is dose-related, is a direct pharmacological effect, resolves reliably with dose reduction alone, and does not recur after steroids are stopped permanently.
• Steroid-triggered relapse of psychotic depression: occurs in someone with latent psychotic vulnerability, may persist beyond steroid reduction, requires antidepressant and/or antipsychotic treatment targeting the underlying disorder, and predicts future relapses regardless of steroid use.

3. The 2022 Prescription Was Clinically Appropriate but Left a Gap

For adolescents with psychotic depression, an antidepressant-antipsychotic combination is the treatment of choice for moderate-severe presentations. NICE guidelines (2023) recommend maintenance treatment for at least 3 months after recovery, and longer in recurrent cases.

• Treatment Options for Psychotic Depression in Adolescents (PMC11780175)

4. The Self-Diagnosis Issue: "Sociopath/Psychopath"

Why This Is Wrong (Clinically and Factually)

• Pervasive disregard for and violation of the rights of others (deceit, manipulation, criminal conduct)
• Lack of empathy, remorse, or guilt
• Cannot be diagnosed before age 18
• Explicitly requires absence of psychotic symptoms - auditory hallucinations are not a feature of ASPD

• She sought her grandmother calling "amma" repeatedly - a profound expression of grief and attachment
• She suffers from voices saying negative things about her - this represents a hostile internal voice, a feature of psychosis, not the exploitative callousness of ASPD
• She has excellent inter-episode social and academic functioning - incompatible with ASPD
• She is distressed by her symptoms and has impaired insight - ASPD by definition involves ego-syntonic behavior, not distress about one's own functioning

Why This Self-Diagnosis Is Dangerous

• Adolescent females are most likely to present with inaccurate self-diagnoses from online sources
• 74% of child/adolescent psychiatrists frequently see patients whose beliefs about their diagnosis are shaped by internet/social media content
• Overidentification with a wrong diagnosis can create a self-defeating thought process, delay treatment-seeking, increase shame, and undermine therapeutic alliance

How to Address This with the Patient

1. Validate her search for an explanation - she was trying to understand something frightening, which is intelligent and normal
2. Correct the self-diagnosis clearly and compassionately: "The voices you are hearing are a symptom of a treatable brain condition, not a character defect or personality disorder. You are not a sociopath. What you experienced in 2022 and what you are experiencing now is the same type of illness - it responds to treatment."
3. Explain the diagnosis at an age-appropriate level - "Your brain is under stress, partly from the eye disease and the medicines treating it. The same brain reacted to a different stress in 2022, when your grandmother died. Both times, it produced these voices and low mood."
4. Emphasize treatability and full recovery - she recovered fully in 2022. The 2022 episode is the proof of concept for treatment working.
5. Restrict harmful internet searching - not with shame, but with a concrete replacement: "Talk to us instead."

5. Revised Management Plan (Updated for the Full Picture)

Acute Phase (Weeks 1-4)

Investigations Still Required (Unchanged from Prior Analysis)

• MRI brain with gadolinium (baseline, and to exclude new CNS pathology)
• EEG
• Anti-NMDA receptor antibodies (serum + CSF) - still necessary to exclude encephalitis
• Full blood count, electrolytes, TFTs, morning cortisol
• Ophthalmology review for VKH status

Medium Term (Months 1-6): Maintenance to Prevent 3rd Episode

• Maintenance treatment for psychotic depression involves antidepressant monotherapy or antidepressant + antipsychotic combination
• Evidence quality is moderate; the meta-analysis did not statistically confirm superiority of combination over monotherapy, but the largest individual RCT showed clear advantage for combination therapy
• For a second episode at age 17, maintenance antidepressant for at least 1-2 years is strongly recommended

Long-Term: Clarify Whether Bipolar or Unipolar

• Hypomanic/manic shifts (especially after steroid changes or antidepressant initiation)
• Family history - first-degree relatives with bipolar disorder would significantly increase the probability

6. The Full Clinical Narrative - Synthesized

A 13-14 year old girl with no prior psychiatric history suffers the sudden loss of her grandmother. In the context of profound grief, she develops a major depressive episode with psychotic features - auditory hallucinations, catatonic behavior (calling "amma" repetitively, withdrawal, decreased self-care), and probable low mood. This is documented, treated acutely with aripiprazole + risperidone + lorazepam, investigated with normal CT/MRI brain. She recovers fully over months. From 2023-2025, she functions excellently - academically and socially - with no psychiatric symptoms.

In November 2025, she develops VKH disease, an autoimmune condition requiring prolonged corticosteroid treatment. She is started on prednisolone 40mg/day, gradually tapering. By April 2026, with irregular adherence causing repeated HPA axis disruption, she develops a second episode of psychosis - auditory hallucinations (voices speaking negatively about her), insomnia, and impaired insight. This second episode has been triggered by the biological stress of her autoimmune illness and the neuroendocrine effects of irregular steroid use, operating on the same underlying psychotic diathesis that caused the 2022 episode.

The patient, frightened and searching for an explanation, has diagnosed herself as a "sociopath" or "psychopath" based on internet searches - a factually incorrect label that she has internalized and that now poses a risk of therapeutic harm if not addressed.

The working diagnosis is: Recurrent Major Depressive Episode with Psychotic Features (2nd episode), steroid-triggered relapse in a biologically vulnerable individual, with prior confirmed episode in 2022 triggered by bereavement. Bipolar I disorder (depressed phase with psychotic features) cannot yet be excluded and should be monitored for.

Summary of What's New from This Update

Bottom line: She is not a sociopath. She is a young person with a treatable recurrent mood disorder with psychotic features, experiencing her second episode under biological stress. She recovered completely once before. With appropriate treatment and maintenance, she is very likely to recover again and do well.

Critical Update: The NEET Examination Context

What This New Information Reveals

Immediate Clinical Triage: What Should Happen NOW

If she is currently in or about to enter the exam:

If she has just finished or will consult after:

Why the Symptom Severity Assessment Changes Here

1. Her hallucinations, though real and distressing, are not fully disorganizing. She has maintained goal-directed behavior, exam preparation, and enough insight to seek consultation.
2. She has partial insight. Despite believing the voices are real (as noted earlier), she is simultaneously functioning at a high enough level to sit a medical entrance exam. This is more consistent with psychotic depression or a mood episode with psychotic features than with florid schizophrenia, where disorganization typically prevents this kind of sustained goal-directed activity.
3. The "impaired insight" noted earlier needs re-evaluation. It may be more nuanced - she believes the voices are real, but she also recognizes that something is wrong (hence Googling symptoms, hence consulting). This partial insight is actually a good prognostic sign.
4. She has been hiding her symptoms. The 3-month duration of hallucinations alongside exam preparation, without earlier escalation of care, strongly suggests she has been minimizing to her family and treating team. This is extremely common in Indian adolescents preparing for competitive exams - the fear of being "taken out of" NEET preparation is a powerful motivator to conceal psychiatric symptoms.

The Prednisolone Re-exposure 2-3 Days Ago

• Acute HPA axis activation (transient cortisol suppression reversed, then relative glucocorticoid excess)
• This crossed the threshold for dopaminergic activation in an already vulnerable brain
• Insomnia (classic early corticosteroid effect, also classic prodrome of mood episode relapse)
• Worsening hallucinations

The NEET Stressor as a Precipitating and Maintaining Factor

• Was already in a 3-month psychotic episode in April-May 2026
• Then had the exam she had been working toward cancelled without warning
• Had to continue preparing for a re-examination date that was uncertain for weeks
• All while managing VKH disease, steroids, and auditory hallucinations

Post-Exam Management Plan (Starting Today)

This Week

• Formal psychiatric assessment as outpatient or day-care patient (not emergency inpatient unless safety concerns arise)
• Reinstate aripiprazole 5mg OD (proven effective in 2022, minimal side effect burden)
• Add low-dose quetiapine 25-50mg at night for insomnia + antipsychotic effect (dual benefit), OR lorazepam 1mg short course only
• Plan SSRI introduction (sertraline 25mg) in 2-4 weeks once antipsychotic established

• Ensure supervised, regular prednisolone 10mg OD (no more gaps)
• Blood tests: FBC, electrolytes, cortisol, TFTs, blood glucose
• Ophthalmology review within 1 week (VKH status check)

• One session dedicated to correcting the sociopath/psychopath self-diagnosis
• Psychoeducation about the 2022-2026 episode pattern and treatability
• Family psychoeducation: explain that hiding symptoms was adaptive but now safe to disclose, and that treatment does not mean the end of academic aspirations

• She should rest this week. Not begin new stressors.
• Sleep hygiene support

Next 1-3 Months

• Continue aripiprazole and SSRI through exam result period (another high-stress window)
• Introduce maintenance antidepressant with plan to continue for at least 1-2 years
• Monthly psychiatric review
• If NEET result is positive and she enters medical school: ensure psychiatric handover to college mental health services with full history, including this complex case

Key Message to Patient and Family

"You sat one of the hardest exams in India while dealing with a serious medical condition that affects how the brain works - and you finished it. That is not what a sociopath does. That is what a determined, intelligent young person with a treatable illness does. Now that the exam is done, we can focus on getting you fully well. You recovered completely in 2022. You will recover again."

Summary: What Today's Context Adds

Prescription Assessment: Olanzapine 2.5mg + Sertraline 25mg × 15 Days

Verdict: Clinically Sound and Evidence-Based

Evidence Base for This Specific Combination

The STOP-PD Trials (The Foundational Evidence)

• Double-blind RCT comparing olanzapine + sertraline vs. olanzapine + placebo
• Olanzapine/sertraline achieved 41.9% remission vs. 23.9% with olanzapine alone (p=0.002, OR=1.28)
• Superior in both younger adults (OR=1.25) and older patients
• Both groups had increases in cholesterol and triglycerides; glucose increased significantly only in younger adults

• After remission on combination therapy, patients randomized to continue olanzapine + sertraline vs. sertraline alone
• Relapse rate: 20% (combination) vs. 55% (sertraline alone) - hazard ratio 0.25 (p<0.001)
• Excess relapse risk concentrated in the first 2 months after stopping olanzapine
• Conclusion: combination therapy should be continued at least 4-6 months after remission

"In the acute phase of psychotic depression, the combination of an antipsychotic and antidepressant is the best treatment option... Evidence from the STOP-PD II trial suggested that withdrawal of olanzapine from sertraline co-therapy worsens outcomes in the medium term."

• Maudsley Prescribing Guidelines, 15th Ed.

Dose Assessment

Olanzapine 2.5mg OD

Sertraline 25mg OD

Duration: 15 Days

• At 15 days: review response, check tolerability, titrate sertraline (25mg → 50mg)
• Olanzapine can stay at 2.5mg if response is adequate, or increase to 5mg if hallucinations persist
• A definite follow-up appointment must be booked now - the 15-day prescription implies the psychiatrist expects to see the patient again in approximately 2 weeks

Specific Considerations for This Patient

1. Timing of Sertraline in Relation to Olanzapine Cover

2. Interaction with Prednisolone

• Sertraline + prednisolone: SSRIs are generally safe with corticosteroids. There is a theoretical increased risk of GI bleeding (both are ulcerogenic), but at prednisolone 10mg this is low risk. Adding a PPI or misoprostol prophylaxis can be considered if the patient develops GI symptoms.
• Olanzapine + prednisolone: both cause metabolic effects (weight gain, hyperglycemia). Blood glucose monitoring is important. At 2.5mg olanzapine and 10mg prednisolone, the combined metabolic risk is manageable but needs monitoring.
• No pharmacokinetic interaction between sertraline and prednisolone or azathioprine of clinical significance.

3. Olanzapine + Azathioprine

4. Weight and Metabolic Monitoring

• Baseline weight, BMI, waist circumference, fasting glucose, fasting lipids
• Repeat at 4 weeks and 12 weeks
• If significant weight gain (>5% body weight in 4 weeks), discuss switching to aripiprazole (lower metabolic burden) once stabilized - consistent with the STOP-PD II editorial recommendation

5. Sleep Timing

What This Prescription Does NOT Address (Gaps to Discuss at Review)

Summary: How to Think About This Prescription

Olanzapine 2.5mg OD (evening)    → Correct antipsychotic for psychotic depression
                                     Appropriate adolescent starting dose
                                     Will address insomnia and hallucinations
                                     Needs titration to 5mg if inadequate response

Sertraline 25mg OD (morning)     → Correct SSRI for psychotic depression
                                     Most RCT-validated pairing with olanzapine (STOP-PD)
                                     Currently sub-therapeutic; titrate to 50-100-150mg
                                     over coming weeks

Duration: 15 days                → Short starter pending review - FINE
                                     A firm 2-week review appointment is essential
                                     Long-term plan: combination for 4-6 months post-remission
                                     Sertraline maintenance for 1-2 years (2nd episode)

1. Assess response to medication
2. Titrate sertraline to 50mg
3. Consider increasing olanzapine to 5mg if hallucinations persist
4. Establish a medium-term maintenance plan
5. Continue to monitor weight and metabolic parameters
6. Address the self-diagnosis belief psychotherapeutically